Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
Month: August 2010
CardioPolymers Continues Development on Heart Failure Device
CardioPolymers (formerly Symphony Medical) of Laguna Hills, Calif., is developing a medical device to reverse CHF in patients who an enlarged left ventricle as a result of mitral valve regurgitation, ischemia, dilated cardiomyopathy and/or other disorders.
Cardiogenesis Lightens the Situation for Angina Sufferers
Cardiogenesis, a medical device company that develops tools for the treatment of ischemic cardiac disease, has helped numerous heart-disease patients with the use of laser therapy.
AesRx Aims at Two Rare Diseases In Growing Orphan Drug Market
The Newton, Mass.-based biopharmaceutical company is developing a small-molecule drug for sickle cell disease.
Adventrx Pharmaceuticals Seeks to Improve Current Cancer Drugs
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
TeleTracking Technologies: Fighting Hospital-Acquired Infections with Patient Flow Software
Hospital-acquired infections (HAIs) are one of the biggest health hazards facing hospitals today.
Nearly 3 Billion Were at Risk for Malaria in 2009
An estimated 2.85 billion people worldwide were at risk of contracting malaria in 2009, according to a new report published Tuesday in the journal PLos Neglected Tropical Diseases.
Scientists Use Herpes Virus to Treat Head and Neck Cancer
Doctors in London successfully used a genetically engineered version of the herpes virus to treat head and neck cancer in a small clinical trial of 17 patients.
Colorectal Cancer Screenings Up, But Higher Numbers Could Save More Lives
More Americans are getting tested for colon cancer and breast cancer, the U.S. Centers for Disease Control (CDC) recently reported, but the numbers still aren’t high enough.